In
the evolving field of drug discovery and development, multiorgans-on-a-chip
and microphysiological systems are gaining popularity owing to their
ability to emulate in vivo biological environments. Among the various
gut-liver-on-a-chip systems for studying oral drug absorption, the
chip developed in this study stands out with two distinct features:
incorporation of perfluoropolyether (PFPE) to effectively mitigate
drug sorption and a unique enterohepatic single-passage system, which
simplifies the analysis of first-pass metabolism and oral bioavailability.
By introducing a bolus drug injection into the liver compartment,
hepatic extraction alone could be evaluated, further enhancing our
estimation of intestinal availability. In a study on midazolam (MDZ),
PFPE-based chips showed more than 20-times the appearance of intact
MDZ in the liver compartment effluent compared to PDMS-based counterparts.
Notably, saturation of hepatic metabolism at higher concentrations
was confirmed by observations when the dose was reduced from 200 μM
to 10 μM. This result was further emphasized when the metabolism
was significantly inhibited by the coadministration of ketoconazole.
Our chip, which is designed to minimize the dead volume between the
gut and liver compartments, is adept at sensitively observing the
saturation of metabolism and the effect of inhibitors. Using genome-edited
CYP3A4/UGT1A1-expressing Caco-2 cells, the estimates for intestinal
and hepatic availabilities were 0.96 and 0.82, respectively; these
values are higher than the known human in vivo values. Although the
metabolic activity in each compartment can be further improved, this
gut-liver-on-a-chip can not only be used to evaluate oral bioavailability
but also to carry out individual assessment of both intestinal and
hepatic availability.